BEDMINSTER, N.J., June 17, 2011 /PRNewswire/ — Omthera
Pharmaceuticals, Inc., a privately-held emerging specialty
pharmaceuticals company, announced today that Jerry Wisler,
President and Chief Executive Officer, will present at the 2011
Wells Fargo Securities Healthcare Conference at the
InterContinental Boston, in Boston, Massachusetts, on Wednesday,
June 22, 2011 at 8:30am ET.
About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera
Pharmaceuticals, Inc. is a privately-held, emerging specialty
pharmaceuticals company focusing its efforts on the clinical
development of new therapies for dyslipidemia. Led by a team
of experts with exceptional experience in developing new therapies
for lipid disorders, Omthera is dedicated to developing innovative
therapies for the millions of patients who have elevated
triglyceride levels and increased risk of cardiovascular
disease. In March 2011, the Company initiated a pivotal Phase
III clinical trial for its lead product candidate, Epanova™,
an Omega-3 fatty acid compound in development as a
triglyceride-lowering adjunct therapy to diet in patients with very
high triglycerides (greater than or equal to 500 mg/dL). Future
planned clinical trials for Epanova include patients with high
triglycerides (greater than or equal to 200 mg/dL and less than or
equal to 500 mg/dL) currently on statin therapy.
For more information, please visit www.omthera.com.Omthera
Contacts:Omthera Media Relations:Douglas Carr
Eric GoldmanFinancial Controller
Rx Communications GroupOmthera Pharmaceuticals
917-322-2563908-741-4323
egoldman@rxir.com
DCarr@Omthera.com
‘/>”/>
SOURCE